Literature DB >> 14707512

A neurological symptom survey of patients with type I Gaucher disease.

G M Pastores1, N L Barnett, P Bathan, E H Kolodny.   

Abstract

Gaucher disease is an inborn error of glycosphingolipid metabolism resulting from deficiency of the lysosomal enzyme glucocerebrosidase. The majority of the patients (with type I disease) do not have primary central nervous system involvement. However, several studies have noted that secondary neurological complications may develop as a consequence of nerve root or spinal cord compression following vertebral body collapse or, for those with coagulation disorders, bleeding within confined compartments. An epidemiological survey was conducted to ascertain the incidence of neurological symptoms in patients with Gaucher disease type I (GD I). The survey included a review of the patients' medical history, an estimate of Gaucher disease severity according to a modified Symptom Severity Index (SSI), and completion of a questionnaire regarding their neurological status and Quality of Life (QoL) according to the SF-36 Health Survey. Seventy-three per cent of respondents were found to have experienced at least one neurological complaint in the preceding 3 months. Adult patients with Gaucher disease often have other medical problems unrelated to their primary diagnosis. Thus, the high incidence of neurological complaints in these patients may be attributable to concurrent medical problems and/or side-effects from concomitant medications. These issues may influence patients' assessment of their disease severity and/or response to treatment.

Entities:  

Mesh:

Year:  2003        PMID: 14707512     DOI: 10.1023/b:boli.0000005623.60471.51

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  11 in total

Review 1.  Gaucher disease: Perspectives on a prototype lysosomal disease.

Authors:  H Zhao; G A Grabowski
Journal:  Cell Mol Life Sci       Date:  2002-04       Impact factor: 9.261

2.  The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study.

Authors:  A M Damiano; G M Pastores; J E Ware
Journal:  Qual Life Res       Date:  1998-07       Impact factor: 4.147

3.  Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.

Authors:  T Cox; R Lachmann; C Hollak; J Aerts; S van Weely; M Hrebícek; F Platt; T Butters; R Dwek; C Moyses; I Gow; D Elstein; A Zimran
Journal:  Lancet       Date:  2000-04-29       Impact factor: 79.321

4.  Neurological involvement in type 1 (adult) Gaucher's disease.

Authors:  R O McKeran; P Bradbury; D Taylor; G Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-02       Impact factor: 10.154

5.  Spinal cord compression secondary to Gaucher's disease.

Authors:  R S Markin; F M Skultety
Journal:  Surg Neurol       Date:  1984-04

6.  Gaucher disease and parkinsonism: a phenotypic and genotypic characterization.

Authors:  N Tayebi; M Callahan; V Madike; B K Stubblefield; E Orvisky; D Krasnewich; J J Fillano; E Sidransky
Journal:  Mol Genet Metab       Date:  2001-08       Impact factor: 4.797

7.  Co-morbidity in Gaucher's disease results of a nationwide enquiry in Spain.

Authors:  J Pérez-Calvo; M Bernal; P Giraldo; M A Torralba; F Civeira; M Giralt; M Pocovi
Journal:  Eur J Med Res       Date:  2000-06-20       Impact factor: 2.175

8.  Neurologic complications of nonneuronopathic Gaucher's disease.

Authors:  R P Grewal; S H Doppelt; M A Thompson; D Katz; R O Brady; N W Barton
Journal:  Arch Neurol       Date:  1991-12

9.  Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients.

Authors:  A Zimran; A Kay; T Gelbart; P Garver; D Thurston; A Saven; E Beutler
Journal:  Medicine (Baltimore)       Date:  1992-11       Impact factor: 1.889

10.  Gaucher disease associated with parkinsonism: four further case reports.

Authors:  Judit Várkonyi; Hanna Rosenbaum; Nicole Baumann; Jennifer J MacKenzie; Zsuzsa Simon; Judith Aharon-Peretz; Jamie M Walker; Nahid Tayebi; Ellen Sidransky
Journal:  Am J Med Genet A       Date:  2003-02-01       Impact factor: 2.802

View more
  12 in total

1.  The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG).

Authors:  P Chérin; C Rose; C de Roux-Serratrice; D Tardy; D Dobbelaere; B Grosbois; E Hachulla; R Jaussaud; R-M Javier; E Noël; P Clerson; A Hartmann
Journal:  J Inherit Metab Dis       Date:  2010-06-02       Impact factor: 4.982

2.  Quality of life of brazilian patients with Gaucher disease and fabry disease.

Authors:  Fabiane Lopes Oliveira; Taciane Alegra; Alicia Dornelles; Bárbara Corrêa Krug; Cristina B O Netto; Neusa Sica da Rocha; Paulo D Picon; Ida Vanessa D Schwartz
Journal:  JIMD Rep       Date:  2012-04-18

3.  Neurological manifestations in patients with Gaucher disease and their relatives, it is just a coincidence?

Authors:  Pilar Giraldo; Jose Luis Capablo; Pilar Alfonso; Beatriz Garcia-Rodriguez; Paz Latre; Pilar Irun; Alicia Saenz de Cabezon; Miguel Pocovi
Journal:  J Inherit Metab Dis       Date:  2011-03-08       Impact factor: 4.982

4.  Evoked potentials and neurocognitive functions in pediatric Egyptian Gaucher patients on enzyme replacement therapy: a single center experience.

Authors:  Azza Abdel Gawad Tantawy; Eman Mounir Sherif; Amira Abdel Moneam Adly; Sahar Hassanine; Amina Hafez Awad
Journal:  J Inherit Metab Dis       Date:  2013-03-19       Impact factor: 4.982

5.  Myopathy in Gaucher disease.

Authors:  Li-Kai Tsai; Yin-Hsiu Chien; Chih-Chao Yang; Wuh-Liang Hwu
Journal:  J Inherit Metab Dis       Date:  2008-01-16       Impact factor: 4.982

Review 6.  'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature.

Authors:  M Biegstraaten; I N van Schaik; J M F G Aerts; C E M Hollak
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.750

7.  Eye movement impairment recovery in a Gaucher patient treated with miglustat.

Authors:  Agostino Accardo; Stefano Pensiero; Giovanni Ciana; Fulvio Parentin; Bruno Bembi
Journal:  Neurol Res Int       Date:  2010-09-26

8.  Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.

Authors:  Gaetano Giuffrida; Rita Lombardo; Ernesto Di Francesco; Laura Parrinello; Francesco Di Raimondo; Agata Fiumara
Journal:  J Med Case Rep       Date:  2016-11-08

9.  Chronic pain in Gaucher disease: skeletal or neuropathic origin?

Authors:  Grazia Devigili; Michele De Filippo; Giovanni Ciana; Andrea Dardis; Christian Lettieri; Sara Rinaldo; Daniela Macor; Alessandro Moro; Roberto Eleopra; Bruno Bembi
Journal:  Orphanet J Rare Dis       Date:  2017-08-31       Impact factor: 4.123

10.  Improvement of life quality measured by Lansky Score after enzymatic replacement therapy in children with Gaucher disease type 1.

Authors:  Magdalena Cerón-Rodríguez; Edgar Barajas-Colón; Lyuva Ramírez-Devars; Claudia Gutiérrez-Camacho; Juan L Salgado-Loza
Journal:  Mol Genet Genomic Med       Date:  2017-10-25       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.